Bristol-Myers Squibb announces restructuring charge at year-end
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb has joined the restructuring efforts seen among other pharmaceutical and healthcare companies in recent years. The US company has announced a restructuring charge of $250-300 million to be taken at year-end as well as possible further charges.